Epidemiology of paraneoplastic neurological syndromes: a population-based study.
Adult
Aged
Aged, 80 and over
Encephalomyelitis
/ epidemiology
Female
Humans
Incidence
Italy
/ epidemiology
Limbic Encephalitis
/ epidemiology
Male
Middle Aged
Neoplasms
/ epidemiology
Paraneoplastic Cerebellar Degeneration
/ epidemiology
Paraneoplastic Syndromes, Nervous System
/ epidemiology
Prevalence
Autoimmune
Encephalitis
Epidemiology
Incidence
Paraneoplastic syndromes
Prevalence
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
29
08
2019
accepted:
12
09
2019
revised:
11
09
2019
pubmed:
26
9
2019
medline:
23
10
2020
entrez:
26
9
2019
Statut:
ppublish
Résumé
The epidemiology of paraneoplastic neurological syndromes (PNS) remains to be defined. We present here the first population-based incidence study and report the clinical spectrum and antibody profile of PNS in a large area in Northeastern Italy. We performed a 9-year (2009-2017) population-based epidemiological study of PNS in the provinces of Udine, Pordenone and Gorizia, in the Friuli-Venezia Giulia region (983,190 people as of January 1, 2017). PNS diagnosis and subgroups were defined by the 2004 diagnostic criteria. Age- and sex-adjusted incidence rates were calculated. We identified 89 patients with a diagnosis of definite PNS. Median age was 68 years (range 26-90), 52% were female. The incidence of PNS was 0.89/100,000 person-years. PNS incidence rates increased over time from 0.62/100,000 person-years (2009-2011), 0.81/100,000 person-years (2012-2014) to 1.22/100,000 person-years (2015-2017). The prevalence of PNS was 4.37 per 100,000. Most common PNS were limbic encephalitis (31%), cerebellar degeneration (28%) and encephalomyelitis (20%). Among antibody (Ab)-positive cases, most frequent specificities included: Yo (30%), Hu (26%), and Ma2 (22%), while the most frequent associated tumors were lung (17%) and breast cancer (16%), followed by lymphoma (12%). PNS developed in 1 in every 334 cancers in our region. Statistically significant associations were observed between cancer type and Ab-specificity (P < 0.001), and between neurological syndrome and Ab-specificity (P < 0.001). This first population-based study found an incidence of PNS that approximates 1/100,000 person-years and a prevalence of 4/100,000. Moreover, the incidence of PNS is increasing over time, probably due to increased awareness and improved detection techniques.
Sections du résumé
BACKGROUND
BACKGROUND
The epidemiology of paraneoplastic neurological syndromes (PNS) remains to be defined. We present here the first population-based incidence study and report the clinical spectrum and antibody profile of PNS in a large area in Northeastern Italy.
METHODS
METHODS
We performed a 9-year (2009-2017) population-based epidemiological study of PNS in the provinces of Udine, Pordenone and Gorizia, in the Friuli-Venezia Giulia region (983,190 people as of January 1, 2017). PNS diagnosis and subgroups were defined by the 2004 diagnostic criteria. Age- and sex-adjusted incidence rates were calculated.
RESULTS
RESULTS
We identified 89 patients with a diagnosis of definite PNS. Median age was 68 years (range 26-90), 52% were female. The incidence of PNS was 0.89/100,000 person-years. PNS incidence rates increased over time from 0.62/100,000 person-years (2009-2011), 0.81/100,000 person-years (2012-2014) to 1.22/100,000 person-years (2015-2017). The prevalence of PNS was 4.37 per 100,000. Most common PNS were limbic encephalitis (31%), cerebellar degeneration (28%) and encephalomyelitis (20%). Among antibody (Ab)-positive cases, most frequent specificities included: Yo (30%), Hu (26%), and Ma2 (22%), while the most frequent associated tumors were lung (17%) and breast cancer (16%), followed by lymphoma (12%). PNS developed in 1 in every 334 cancers in our region. Statistically significant associations were observed between cancer type and Ab-specificity (P < 0.001), and between neurological syndrome and Ab-specificity (P < 0.001).
CONCLUSIONS
CONCLUSIONS
This first population-based study found an incidence of PNS that approximates 1/100,000 person-years and a prevalence of 4/100,000. Moreover, the incidence of PNS is increasing over time, probably due to increased awareness and improved detection techniques.
Identifiants
pubmed: 31552550
doi: 10.1007/s00415-019-09544-1
pii: 10.1007/s00415-019-09544-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
26-35Références
J Neurooncol. 2015 Oct;125(1):197-206
pubmed: 26307447
Handb Clin Neurol. 2016;138:225-38
pubmed: 27637961
J Neurol. 2019 Feb;266(2):398-410
pubmed: 30498914
Neuroepidemiology. 2018;50(3-4):153-159
pubmed: 29558746
Oncologist. 2007 Jan;12(1):20-37
pubmed: 17227898
Eur J Paediatr Neurol. 2017 Mar;21(2):312-317
pubmed: 27666466
Epidemiol Prev. 2015 May-Jun;39(3 Suppl 1):21-9
pubmed: 26405773
Neurol Neuroimmunol Neuroinflamm. 2019 Aug 7;6(6):
pubmed: 31454760
Brain. 2009 Jul;132(Pt 7):1723-33
pubmed: 19506068
JAMA. 2016 Oct 11;316(14):1488-1489
pubmed: 27727364
Brain. 2004 Aug;127(Pt 8):1831-44
pubmed: 15215214
N Engl J Med. 2003 Oct 16;349(16):1543-54
pubmed: 14561798
N Engl J Med. 2018 Mar 1;378(9):840-851
pubmed: 29490181
Brain. 2003 Jun;126(Pt 6):1409-18
pubmed: 12764061
J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1135-40
pubmed: 15258215
Arch Neurol. 2011 Oct;68(10):1282-9
pubmed: 21670387
J Neurol. 2019 Jan;266(1):195-206
pubmed: 30460450
Neurology. 2017 May 2;88(18):1736-1743
pubmed: 28381508
Neurology. 2017 Apr 4;88(14):1340-1348
pubmed: 28258082
Curr Drug Targets Immune Endocr Metabol Disord. 2004 Jun;4(2):141-8
pubmed: 15180454
J Neurol Neurosurg Psychiatry. 2010 Aug;81(8):937-9
pubmed: 20562403
Neuromuscul Disord. 2016 Jan;26(1):41-6
pubmed: 26573434
Arch Neurol. 2010 Mar;67(3):330-5
pubmed: 20212230
J Neurol. 2018 Mar;265(3):669-677
pubmed: 29383516
Neurology. 2017 Mar 14;88(11):1012-1020
pubmed: 28202703
Epilepsia. 2019 Aug;60(8):1508-1525
pubmed: 31283859
Neurology. 2017 Feb 7;88(6):514-524
pubmed: 28062719
Orphanet J Rare Dis. 2007 May 04;2:22
pubmed: 17480225
Surg Neurol Int. 2015 Nov 16;6:171
pubmed: 26629397
Lancet Neurol. 2016 Apr;15(4):391-404
pubmed: 26906964
J Neurooncol. 2019 Jan;141(2):431-439
pubmed: 30607708
Neuroepidemiology. 2017;48(3-4):119-123
pubmed: 28641305
Malays J Med Sci. 2000 Jan;7(1):10-5
pubmed: 22844209
J Neuroimmunol. 2018 Apr 15;317:90-94
pubmed: 29336839
J Neurol Sci. 2015 Mar 15;350(1-2):105-6
pubmed: 25661887
N Engl J Med. 2019 Jul 4;381(1):47-54
pubmed: 31269365
Popul Stud (Camb). 1966 Mar;19(3):281-95
pubmed: 22077511
Ann Neurol. 2018 Jan;83(1):166-177
pubmed: 29293273